Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment

Use of Pharmacotherapy to Improve Weight Loss in Early Non-responders to Behavioral Treatment

This is a two-phase study. Phase 1 will evaluate obesity-related behavioral and biological characteristics as potential predictors of response to behavioral treatment (BT) for weight loss. Phase 2 is a double-blind, placebo-controlled, RCT to test whether adding weight loss medication to BT improves 24-week weight loss, as compared to BT with placebo, in subjects identified as having suboptimal early weight loss after 4 weeks of individual behavioral weight control. All participants, regardless of their early weight loss, will receive the same BT program of diet, physical activity, and behavior therapy for weight loss for an additional 24 weeks (28 total weeks of treatment).

Study Overview

• Status: Completed
• Conditions: Obesity
• Intervention / Treatment: Behavioral: Behavioral Treatment; Drug: Placebo; Drug: Phentermine 15 MG

Detailed Description

Subjects will be a total of 150 adults, aged 21-70 years, with a body mass index (BMI) of 31 kg/m2 or above (28 kg/m2 with an obesity-related comorbidity). In phase 1, eligible subjects will complete questionnaires and an in-person baseline assessment of obesity-related behavioral characteristics (satiety, hunger, the relative reinforcing value of food [RRVfood], and impulsivity [delay discounting]), neuropeptides, and gastric emptying. After this baseline assessment, participants will begin an initial 4-week behavioral treatment (BT) "run-in" delivered individually in 20-30 minute weekly sessions (delivered virtually).

The primary goal of phase 1 will be to evaluate baseline satiety, postprandial change in GLP-1, and gastric emptying as predictors of percent weight loss after 4 weeks of BT. We will also examine whether these variables predict categorization as a suboptimal early responder to BT (e.g., <2.0% loss; co-primary outcome).

Secondary endpoints of phase 1 are percent weight loss from the start of the BT run-in (week -4) to randomization (week 0) and categorization as a suboptimal early responder, as predicted by additional behavioral characteristics (hunger as measured by VAS ratings, RRVfood as measured using a computer task, and impulsivity as measured using a delay discounting computer task) and neuropeptides (higher fasting ghrelin, lower fasting leptin, and lower postprandial changes in insulin and PYY).

In phase 2, suboptimal early responders (based on weight loss during the BT run-in) will be randomly assigned to 24 weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg). Both treatment groups will continue to attend 20-30 minute individual BT sessions (delivered virtually), weekly for the first 12 weeks and every other week for the last 12 weeks (total of 18 visits). Both treatment groups will also take once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period. Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial.

The assessments administered at baseline - questionnaires, including behavioral testing, blood draws, and measurements of body weight - will be repeated at randomization (week 0) and at week 24.

The primary endpoint of phase 2 is change in body weight (i.e., % reduction in initial weight), as measured from randomization to week 24, among suboptimal early responders assigned to BT+P vs. BT+M. A randomized sample size of 50 non-responders (25 per group), assuming a 20% attrition rate, will give us 81.5% power to detect between-treatment group differences at week 24 of 4.5% (effect size: d = 0.82).

Secondary endpoints of phase 2 will include change in body weight in kg from randomization to week 24, as well as the portion of suboptimal early responders who achieve a post-randomization loss of ≥ 5% and ≥ 10% of initial body weight. We will also examine differences between suboptimal early responders treated with BT+M vs. BT+P in changes in hunger, satiety, the reinforcing efficacy of food, and impulsivity between randomization and week 24. A comparison will also be made in percent weight loss from randomization to week 24 between suboptimal early responders treated with BT+M and early responders treated with BT alone.

If you are interested in participating in this study, information and a link to contact the research team can be found here: https://clinicalresearch.itmat.upenn.edu/3XOX/ or you can call us at the numbers listed below.

• Study Type: Interventional
• Enrollment (Actual): 147
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • University of Pennsylvania Center for Weight and Eating Disorders

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. BMI ≥ 31 kg/m² (or 28 kg/m2 with obesity-related comorbidity)
2. Age ≥ 21 years and ≤ 70 years

3. Eligible female patients will be:

   • non-pregnant, evidenced by a negative urine pregnancy test
   • non-lactating
   • surgically sterile or postmenopausal, or they will agree to continue to use an accepted method of birth control during the study. Acceptable methods of birth control are: hormonal contraceptives; double barrier method (condom with spermicide or diaphragm with spermicide); intrauterine device; surgical sterility; abstinence; and/or postmenopausal status (defined as at least 2 years without menses).

4. Subjects must:

   • have a primary care provider (PCP) who is responsible for providing routine care
   • understand and be willing to comply with all study-related procedures and agree to participate in the study by giving written informed consent
   • plan to remain in the Philadelphia area for the next 9 months or more

Exclusion Criteria:

1. Pregnant or nursing, or plans to become pregnant in the next 9 months.
2. Uncontrolled hypertension (systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg)
3. Type 1 diabetes
4. Type 2 diabetes
5. A fasting blood glucose > 126 mg/dL (on second assessment after first elevated value)
6. History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, or heart block greater than first degree
7. Clinically significant hepatic or renal disease
8. Hyperthyroidism
9. Other thyroid disease, not controlled
10. History of malignancy (except for non-melanoma skin cancer) in past 5 years
11. Narrow angle glaucoma
12. Presence or history of marked agitation
13. Current severe major depressive episode (BDI-II score ≥ 29), current active suicidal ideation, or history of suicide attempts within the past 5 years.
14. Any severity of thought or bipolar disorder, or bulimia nervosa.
15. Psychiatric hospitalization within the past 6 months
16. Self-reported alcohol or substance abuse within the past 6 months, including at-risk drinking (current consumption of ≥ 14 alcoholic drinks per week)
17. Past year history of drug abuse
18. Use in the past 2 weeks of monoamine oxidase inhibitors
19. Current use of serotonin-norepinephrine reuptake inhibitors (SNRIs; e.g. venlafaxine, duloxetine, desvenlafaxine, milnacipran, levomilnacipran).
20. Use in past 6 months of medications known to induce significant weight loss (i.e., prescription weight loss medications) or weight gain (e.g., chronic use of oral steroids, second generation antipsychotics)
21. Loss of ≥ 5% of initial body weight within the past 6 months
22. History of (or plans for) bariatric surgery (e.g., roux en y gastric bypass, sleeve gastrectomy, gastric banding), endoscopic intragastric balloon, or aspire assist.
23. Inability to walk 5 blocks comfortably or engage in some other form of aerobic activity (e.g., swimming)
24. Known or suspected allergy to sympathomimetic amines or related products
25. The receipt of any investigational drug within 6 months prior to this trial
26. Previous participation in this trial (e.g., randomized and failed to participate)
27. Changes to any chronic medication (type or dosage) within the past 3 months.
28. Any serious or unstable medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safety or successful participation in the study

Other Therapy: Subjects will be expected to use medications (prescribed by their PCP) to control traditional cardiometabolic risk factors (e.g., hypertension, hypercholesterolemia, etc) and other co-morbid conditions, with the exception of medications listed above under "exclusions." In all cases, the subjects' PCP will be asked at the study's outset to keep medication does constant throughout the study, whenever possible. Subjects will be expected to have been on their medication regimen (including the dose) for 3 months prior to beginning the BT program.

To be eligible to participate in the randomized phase of the trial, subjects must also:

1. Complete at least 3 out of 4 treatment sessions during the 4-week BT run-in and attend a randomization visit. Attending an in-person makeup session within one week of a missed visit will count as having attended the run-in visit.
2. Lose < 2.0% of initial weight during the 4-week BT run-in.

Early BT responders who lose>=2% during the BT run-in will be offered the same 24-week BT program, but will not receive study medication or be included in the randomized trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Behavioral Treatment + Placebo; All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period. Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial.	Behavioral: Behavioral Treatment; Behavioral treatment (BT) for weight loss includes diet and physical activity recommendations and behavior therapy strategies. All participants will complete an initial 4-week BT run-in, delivered in individual, 20-30 minute weekly sessions. After the end of the run-in, participants will be offered an additional 24 weeks of 20-30 minute individual BT sessions, occurring weekly for the first 12 weeks and every other week for the last 12 weeks (total of 18 visits).; Other Names: Lifestyle modification; Behavioral weight loss; Drug: Placebo; The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.; Other Names: Placebo for medication
Active Comparator: Behavioral Treatment + Medication; All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period. Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial.	Behavioral: Behavioral Treatment; Behavioral treatment (BT) for weight loss includes diet and physical activity recommendations and behavior therapy strategies. All participants will complete an initial 4-week BT run-in, delivered in individual, 20-30 minute weekly sessions. After the end of the run-in, participants will be offered an additional 24 weeks of 20-30 minute individual BT sessions, occurring weekly for the first 12 weeks and every other week for the last 12 weeks (total of 18 visits).; Other Names: Lifestyle modification; Behavioral weight loss; Drug: Phentermine 15 MG; The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.; Other Names: Medication

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 1: Percent weight loss	Co-primary outcomes - phase 1	Week -4 (start of BT run-in) to week 0 (randomization)
Phase 1: Number of participants who are categorized as early non-responders at randomization, based on percent weight loss	Co-primary outcomes - phase 1	Week -4 (start of BT run-in) to week 0 (randomization)
Phase 1: Baseline satiety, as measured by visual analogue scales (range 0-100 mm) during a test meal; satiety quotient = [(fasting rating before preload - 60 min post-preload rating)] / (energy content of preload) x 100.	Primary predictor variable - phase 1	Baseline (week -5)
Phase 1: Baseline postprandial change in GLP-1 during a test meal	Primary predictor variable - phase 1	Baseline
Phase 1: Baseline gastric emptying during a test meal (acetaminophen test)	Primary predictor variable - phase 1	Baseline
Phase 2: Percent weight loss	Primary outcomes - phase 2	Week 0 (randomization) to week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 1: Baseline hunger, as measured by visual analogue scales (range 0-100 mm, higher = more hunger) during a test meal	Secondary predictor variable - phase 1	Baseline
Phase 1: Baseline relative reinforcing value of food (computer task), number of food reinforcer points earned	Secondary predictor variable - phase 1	Baseline
Phase 1: Baseline delay discounting (computer task), area under the curve representing the ratio of immediate reward size to time delay	Secondary predictor variable - phase 1	Baseline
Phase 1: Baseline implicit wanting of food, reaction time on Leeds Food Preference Questionnaire	Secondary predictor variable - phase 1	Baseline
Phase 1: Baseline fasting ghrelin	Secondary predictor variable - phase 1	Baseline
Phase 1: Baseline fasting leptin	Secondary predictor variable - phase 1	Baseline
Phase 1: Baseline postprandial change in insulin during a test meal	Secondary predictor variable - phase 1	Baseline
Phase 1: Baseline postprandial change in peptide YY during a test meal	Secondary predictor variable - phase 1	Baseline
Phase 2: Weight loss (kg)	Secondary outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Number of participants with a weight loss of 5% or greater of randomization body weight at week 24	Secondary outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Number of participants with a weight loss of 10% or greater of randomization body weight at week 24	Secondary outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Change in satiety, as measured by visual analogue scales (range 0-100 mm) during a test meal; satiety quotient = [(fasting rating before preload - 60 min post-preload rating)] / (energy content of preload) x 100.	Secondary outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Change in hunger, as measured by visual analogue scales (range 0-100 mm, higher=more hunger) during a test meal	Secondary outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Change in relative reinforcing value of food (computer task), number of food reinforcer points earned	Secondary outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Change in delay discounting (computer task), area under the curve representing the ratio of immediate reward size to time delay	Secondary outcomes - phase 2	Week 0 (randomization) to week 24

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 1: Baseline eating behavior as measured by The Eating Inventory (EI); Dietary restraint subscale (scored 0-21 higher=more restraint), Disinhibition sub scale (scored 0-16 higher=more disinhibition), Hunger sub scale (scored 0-14 higher=more hunger)	Exploratory predictor variable - phase 1	Baseline
Phase 1: Baseline appetite ratings (ratings of appetite during the past week using visual analogue scales, scored 0-100 mm, higher=greater amount or frequency)	Exploratory predictor variable - phase 1	Baseline
Phase 1: Baseline reinforcing value of food as measured by the Power of Food Scale (PFS; range 1-5, higher=greater power of food)	Exploratory predictor variable - phase 1	Baseline
Phase 1: Baseline sensitivity to reward as measured by the Behavioral Inhibition/Activation Scale (BIS/BAS) (BIS subscale range 7-28, higher = greater inhibition; BAS reward responsiveness sub scale range 5-20, higher=greater reward responsiveness, etc)	Exploratory predictor variable - phase 1	Baseline
Phase 1: Baseline impulsivity as measured by The Barratt Impulsiveness Scale (BIS-15, range 15-60, higher= more impulsiveness)	Exploratory predictor variable - phase 1	Baseline
Phase 1: Baseline binge eating as measured by The Questionnaire on Eating and Weight Patterns (QEWP-5); Measure categorizes participants based on whether they may meet diagnostic criteria for binge eating disorder	Exploratory predictor variable - phase 1	Baseline
Phase 1: Baseline craving frequency as measured by the Food Craving Q Trait - Reduced	Exploratory predictor variable - phase 1	Baseline
Phase 1: Baseline emotional eating as measured by the Dutch Eating Behaviour Questionnaire (DEBQ)	Exploratory predictor variable - phase 1	Baseline
Phase 1: Baseline perceived barriers to healthy eating and physical activity (Scale by Welsh et al., 2012)	Exploratory predictor variable - phase 1	Baseline
Phase 1: Baseline Weight Efficacy Life-Style Questionnaire (WEL)	Exploratory predictor variable - phase 1	Baseline
Phase 1: Baseline SCI Exercise Self Efficacy Scale (ESES)	Exploratory predictor variable - phase 1	Baseline
Phase 1: Randomization Ball and Crawford Social Support Scale	Exploratory predictor variable - phase 1	Randomization (week 0)
Phase 1: Baseline food addiction using the Yale Food Addiction Scale (YFAS)	Exploratory predictor variable - phase 1	Baseline
Phase 1: The reinforcing efficacy of high- and low-calorie food	Exploratory predictor variable - phase 1	Baseline
Phase 1: Baseline sleep hours survey	Exploratory predictor variable - phase 1	Baseline
Phase 1: Baseline Perceived Stress Scale	Exploratory predictor variable - phase 1	Baseline
Phase 1: Baseline anxiety as measured by the GAD-7	Exploratory predictor variable - phase 1	Baseline
Phase 1: Baseline general mindfulness and acceptance as measured using the Philadelphia Mindfulness Scale	Exploratory predictor variable - phase 1	Baseline
Phase 2: Change in blood pressure	Exploratory outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Change in pulse	Exploratory outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Change in waist circumference	Exploratory outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Change in triglycerides	Exploratory outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Change in HDL and LDL cholesterol	Exploratory outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Change in fasting blood sugar	Exploratory outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Change in appetite ratings (ratings of appetite during the past week using visual analogue scales, scored 0-100 mm)	Exploratory outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Change in quality of life as measured by the Impact of Weight on Quality of Life (IWQOL)	Exploratory outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Change in depressive symptoms as measured by the Patient Health Questionnaire (PHQ-9)	Exploratory outcomes - phase 2	Week 0 (randomization) to week 24
Phase 2: Change in physical activity using the Paffenbarger Physical Activity Questionnaire	Exploratory outcomes - phase 2	Week 0 (randomization) to week 24

Collaborators and Investigators

• Sponsor: University of Pennsylvania
• Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Investigators: Principal Investigator: Jena S Tronieri, PhD, Perelman School of Medicine at the University of Pennsylvania

Study record dates

Study Major Dates

• Study Start (Actual): July 15, 2019
• Primary Completion (Actual): May 25, 2022
• Study Completion (Actual): May 25, 2022

Study Registration Dates

• First Submitted: December 5, 2018
• First Submitted That Met QC Criteria: December 13, 2018
• First Posted (Actual): December 19, 2018

Study Record Updates

• Last Update Posted (Actual): September 14, 2022
• Last Update Submitted That Met QC Criteria: September 13, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Keywords: Weight Loss; Body Weight; Signs and Symptoms; Incretins; Hormones; Anti-Obesity Agents; phentermine; Body Weight Changes; Appetitive Behavior; Hypoglycemic agents; Appetite Depressants
• Additional Relevant MeSH Terms: Body Weight; Body Weight Changes; Weight Loss; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Appetite Depressants; Anti-Obesity Agents; Central Nervous System Stimulants; Sympathomimetics; Phentermine
• Other Study ID Numbers: 832077

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No